RanjanaHiraAdvaniMD

Oncology • Palo Alto, CA

Hematologic Oncology

Professor, Medicine - Oncology, Stanford University Medical Center

Join to view full profile

Dr. Advani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Advani's full profile

Already have an account?

Office
875 Blake Wilbur Dr
Palo Alto, CA 94304
Phone+1 650-724-8372
Is this information wrong?

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1994 - 1998
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1987 - 1991
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1989 - 1990
Grant Medical CollegeClass of 1983

Certifications & Licensure

CA State Medical License 1988 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Rituximab in Treating Patients With Hodgkin's Lymphoma Start of enrollment: 1999 Jan 01
Completed
Phase 2
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma Start of enrollment: 2006 Jan 24
Terminated
Phase 2
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL Start of enrollment: 2009 Aug 01
Completed
Phase 2
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Start of enrollment: 2011 Jul 06
Completed
Phase 2
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Start of enrollment: 2013 May 24
Terminated
Phase 2
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Start of enrollment: 2011 May 01
Completed
Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Start of enrollment: 2011 Nov 01
Active, not recruiting
Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
A Safety Study of SGN-CD19A for B-Cell Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2014 Mar 07
Suspended
Phase 1, Phase 2
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Start of enrollment: 2014 Jul 07
Completed
Phase 3
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Start of enrollment: 2015 Sep 28
Completed
Phase 1, Phase 2
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Start of enrollment: 2016 May 13
Active, not recruiting
Phase 2
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. Start of enrollment: 2018 Oct 14
Recruiting
Roles: Contact, Principal Investigator
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma Start of enrollment: 2024 Feb 06
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relap...
Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, Kamil J Cygan, Darius Scott, Se Jeong, Lauren Boucher, Namita T Gupta, Suraj Gupta, Christina Adler, Max S...> ;Journal for Immunotherapy of Cancer. 2024 Mar 21
A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis.
Shree, T., Haebe, S., Czerwinski, D., Eckhert, E., Day, G., Sathe, A., Grimes, S., Frank, M., Maeda, L., Alizadeh, A., Advani, R., Hoppe, R., Long, S., Martin, B., Oza...> ;Blood Advances. 2024 Jan 9
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North Am...
Barr, P. M., Barr, P. M., Julie M Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K Link, Me...> ;Journal of Hematology & Oncology. 2023 Dec 16
3 citations
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.
Jin, M., Stefan K Alig, Mohammad Shahrokh Esfahani, Andrea Garofalo, Michael Yu Li, Cédric Rossi, Tim Flerlage, Jamie E Flerlage, Ragini Adams, Michael S Binkley, Navi...> ;Nature. 2024 Jan 1
3 citations
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Babis Andreadis, Nancy L Bartlett, L Elizabeth Budde, Paolo F Caimi, Julie E Chang, Beth Christia...> ;Journal of the National Comprehensive Cancer Network. 2023 Nov 1
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.
Sanjal H Desai, Michael A Spinner, Andrew M Evens, Alice Sykorova, Veronika Bachanova, Gaurav Goyal, Brad Kahl, Kathleen Dorritie, Jacues Azzi, Vaishalee P Kenkre, Che...> ;Blood Advances. 2023 Dec 12
2 citations
Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
Gaurav Varma, Jordan Goldstein, Ranjana H Advani> ;Hematological Oncology. 2023 Jun 1
7 citations
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
Rezvani, A. R., Michael A Spinner, R A Sica, John S Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J Frank, Laura J Johnston, David B Miklos, Lori S Muffly, ...> ;Blood. 2023 Jun 1
3 citations
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
Robert Stuver, Steven M Horwitz, Ranjana H Advani, Julie M Vose, Hun Ju Lee, Neha Mehta-Shah, Jasmine M Zain, Bradley Haverkos, Mary Jo Lechowicz, Alison J Moskowitz, ...> ;British Journal of Haematology. 2023 Aug 1
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.
Greg Hapgood, Monica Civallero, Yana Stepanishyna, Julie Vose, Monica Elena Cabrera, Ranjana H Advani, Stefano A Pileri, Martina Manni, Steven M Horwitz, Francine M Fo...> ;Blood Advances. 2023 Sep 12
Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment.
Wendy B C Stevens, G Tjitske Los-de Vries, Carole Langois-Jacques, Andrew J Clear, Phylicia Stathi, Birgitta Sander, Andreas Rosenwald, Maria Calaminici, Eva Hoster, W...> ;Hemasphere. 2023 Apr 1
1 citations
SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Michael S Binkley, Ranjana H Advani> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jul 1
6 citations
Report of consensus panel 1 from the 11International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients.
Christian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, Ranjana Advani, Suzanne O Arulogun, Andrew R Branagan, Xinxin Cao, Shirley D'Sa, Jian Hou, Prashant Kapoor, ...> ;Seminars in Hematology. 2023 Mar 1
4 citations
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Sanjal H Desai, Michael A Spinner, Kevin David, Veronika Bachanova, Gaurav Goyal, Brad Kahl, Kathleen Dorritie, Jacques Azzi, Vaishalee P Kenkre, Sally Arai, Cheryl Ch...> ;American Journal of Hematology. 2023 Mar 1
Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma bio...
Yasodha Natkunam, Daphne de Jong, Pedro Farinha, Philippe Gaulard, Wolfram Klapper, Andreas Rosenwald, Birgitta Sander, Reuben Tooze, Ranjana Advani, Catherine Burton,...> ;Histopathology. 2023 Jun 1
Investigating and modeling positron emission tomography factors associated with large cell transformation from low-grade lymphomas.
Jean-Pierre Obeid, Susan M Hiniker, Joseph Schroers-Martin, H Henry Guo, Hyunsoo Joshua No, Everett J Moding, Ranjana H Advani, Ash A Alizadeh, Richard T Hoppe, Michae...> ;Ejhaem. 2023 Feb 1
7 citations
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
H Miles Prince, Martin Hutchings, Eva Domingo-Domenech, Dennis A Eichenauer, Ranjana Advani> ;Annals of Hematology. 2023 Jan 1
3 citations
Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.
Kunwar Singh, Lhara S Lezama, Jason Kurzer, Jean Oak, Liora M Schultz, Ann Walkush, Tse-Chang Cheng, Everett H Chen, William A May, Cheryl Chang, Michael P Link, Ranja...> ;The American Journal of Surgical Pathology. 2023 Jan 1
54 citations
Genomic profiling for clinical decision making in lymphoid neoplasms.
Laurence de Leval, Ash A Alizadeh, P Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M Horwitz, Ari M Melnick, William G Morice, Ryan ...> ;Blood. 2022 Nov 24
14 citations
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Kerry J Savage, Steven M Horwitz, Ranjana Advani, Jacob Haaber Christensen, Eva Domingo-Domenech, Giuseppe Rossi, Franck Morschhauser, Onder Alpdogan, Cheolwon Suh, Ke...> ;Blood Advances. 2022 Oct 11
8 citations
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
Deepa Jagadeesh, Steve Horwitz, Nancy L Bartlett, Youn Kim, Eric Jacobsen, Madeleine Duvic, Meredith Little, William Trepicchio, Keenan Fenton, Matthew Onsum, Julie Li...> ;The Oncologist. 2022 Oct 1
11 citations
Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV.
G Tjitske Los-de Vries, Wendy B C Stevens, Erik van Dijk, Carole Langois-Jacques, Andrew J Clear, Phylicia Stathi, Margaretha G M Roemer, Matias Mendeville, Nathalie J...> ;Blood Advances. 2022 Sep 27
435 citations
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Elias Campo, Elaine S Jaffe, James R Cook, Leticia Quintanilla-Martinez, Steven H Swerdlow, Kenneth C Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, St...> ;Blood. 2022 Sep 15
6 citations
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, Seongho Kim, Krish Patel, Nancy L Bartlett, Mary-Kate Malecek, Marcus P Watkins, Kami J Maddocks, David A Bond,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Jul 1
61 citations
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymp...
Rajat Bannerji, Jon E Arnason, Ranjana H Advani, Jennifer R Brown, John N Allan, Stephen M Ansell, Jeffrey A Barnes, Susan M O'Brien, Julio C Chávez, Johannes Duell, A...> ;The Lancet. Haematology. 2022 May 1
Join now to see all

Journal Articles

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine

Abstracts/Posters

Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Response to A+CHP by CD30 expression in the ECHELON-2 trial.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E0, the Bortezomib Ind...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Studyof Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monot...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hodgkin Lymphoma: Beyond ABVD for Everyone
60th American Society of Hematology Annual Meeting - 12/1/2018
Evolving Treatment Paradigms of Early-Stage Hodgkin Lymphoma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 res...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
17th International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma®
Physicians' Education Resource, LLC, New York, New York - 2/15/2013
5th Annual T-cell Lymphoma Forum
Jonathan Wood & Associates, San Francisco, California - 1/24/2013
Join now to see all

Press Mentions

Non-Chemo Regimen Highly Active in R/R Hodgkin LymphomaAugust 23rd, 2021
International Prognostic Tool Predicts Outcomes in Angioimmunoblastic T-cell LymphomaJune 1st, 2021
CD47 Blocker Reverses Rituximab Resistance in LymphomaNovember 1st, 2018
Join now to see all